Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial

Table 2 Effects of tofogliflozin on brachial-ankle pulse wave velocity

	Tofogliflozin group (n = 74)	Conventional group (n = 66)	Treatment effect (tofogliflozin–conventional treatment) (mean change [95% CI])	p value between groups
Right baPWV
Change from baseline at week 52 (cm/s)	− 15.4 (38.1)	50.0 (38.3)	− 65.4 (–163.1, 32.2)	0.19
Change from baseline at week 104 (cm/s)	− 70.6 (31.3) ^*	38.7 (30.2)	− 109.3 (–184.3, –34.3)	0.005
Left baPWV
Change from baseline at week 52 (cm/s)	1.5 (36.9)	63.7 (37.3)	− 62.2 (–157.1, 32.7)	0.20
Change from baseline at week 104 (cm/s)	− 32.6 (30.7)	65.8 (29.8)*	− 98.3 (–172.6, –24.1)	0.010
Mean baPWV
Change from baseline at week 52 (cm/s)	− 7.7 (36.7)	56.7 (37.0)	− 64.4 (–158.8, 29.9)	0.18
Change from baseline at week 104 (cm/s)	− 52.5 (30.1)	52.2 (29.1)	− 104.7 (–177.0, –32.4)	0.005

Data are presented as mean (SE) unless stated otherwise. Comparisons of baPWV values during treatment with those at baseline were performed using a one-sample t-test based on the mixed-effects model for repeated measures. *p < 0.05, ^#p < 0.01, ^§p < 0.001. Differences in delta change in baPWV from baseline to weeks 52 and 104 between groups at each point (treatment effect) were analyzed with the mixed-effects model for repeated measures. Treatment group, week, interactions between treatment group and week, age, sex, use of insulin at baseline, and baseline baPWV were included as fixed effects
baPWV brachial-ankle pulse wave velocity

ISSN: 1475-2840